---
{"dg-publish":true,"permalink":"/2-areas/university/rheumatoid-arthritis/","created":"2023-02-12T22:00:50.817+07:00","updated":"2025-10-06T19:52:12.968+07:00"}
---

Auranofin ‡πÅ‡∏ó‡∏ö‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÉ‡∏ä‡πâ‡πÅ‡∏•‡πâ‡∏ß‡πÉ‡∏ô‡∏ó‡∏∏‡∏Å‡∏ß‡∏±‡∏ô‡∏ô‡∏µ‡πâ  ‡∏ñ‡πâ‡∏≤ MTX ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏Å‡πá‡∏à‡∏∞‡πÑ‡∏õ‡∏™‡∏ô‡πÉ‡∏à sulfinsalazine ‡∏´‡∏£‡∏∑‡∏≠ leflunomide

## Characteristics
-   ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö ‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á ‡∏û‡∏ö‡∏ö‡πà‡∏≠‡∏¢
-   ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏Ç‡πâ‡∏≠ ‡∏Ç‡πâ‡∏≠‡∏û‡∏¥‡∏Å‡∏≤‡∏£ ‡∏ú‡∏¥‡∏î‡∏£‡∏π‡∏õ ‡∏†‡∏≤‡∏ß‡∏∞‡∏ó‡∏∏‡∏û‡∏û‡∏•‡∏†‡∏≤‡∏û **‡πÄ‡∏û‡∏¥‡πà‡∏°‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡πÄ‡∏Å‡∏¥‡∏î‡πÇ‡∏£‡∏Ñ CVD ‡∏≠‡∏µ‡∏Å**
-   ‡∏û‡∏ö‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 35-50 ‡∏õ‡∏µ
-   ‡∏û‡∏ö‡πÉ‡∏ô female 2-3 : 1 male _**autoimmune ‡∏°‡∏±‡∏Å‡∏û‡∏ö‡πÉ‡∏ô‡∏ú‡∏ç‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏ú‡∏ä**_
## Risk Factors
-   ‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏° ‚Üí ‡πÅ‡∏ù‡∏î‡πÅ‡∏ó‡πâ‡∏à‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏°‡∏≤‡∏Å ‡∏ñ‡πâ‡∏≤‡∏û‡∏µ‡πà‡∏ô‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏Ñ‡πà‡∏≠‡∏¢‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏Ç‡∏ô‡∏≤‡∏î‡∏ô‡∏±‡πâ‡∏ô
	-   human leukocyte antigen (HLA) ‚Üí HLA-DRB1 (‡πÅ‡∏ï‡πà‡∏û‡∏ö‡πÉ‡∏ô europe ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤)
	-   Epigenetics Modification
-   Hormone ‚Üí ‡∏Ñ‡∏¥‡∏î‡∏ß‡πà‡∏≤ estogen ‡πÄ‡∏õ‡πá‡∏ô risk / ‡πÅ‡∏ï‡πà testosterone ‡πÄ‡∏õ‡πá‡∏ô protective factor
	-   ‡∏ï‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á ‡πÇ‡∏£‡∏Ñ‡πÄ‡∏Ç‡πâ‡∏≤‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏á‡∏ö ‡∏Å‡∏≤‡∏£‡∏ó‡∏≤‡∏ô‡∏¢‡∏≤‡∏Ñ‡∏∏‡∏°‡∏Å‡πá‡∏ä‡πà‡∏ß‡∏¢‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô ‡πÅ‡∏ï‡πà‡∏ï‡∏≠‡∏ô‡∏Ñ‡∏•‡∏≠‡∏î‡∏°‡∏±‡∏Å‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏≤‡∏£‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö (‡∏á‡∏á‡πÄ‡∏•‡∏¢)
-   environment
	-   smoking ‚Üí ‡∏°‡∏µ‡∏ú‡∏•‡∏Å‡∏±‡∏ö epigenetics ‡∏î‡πâ‡∏ß‡∏¢
	-   exposure to chemical substance e.g. silica (‡∏¢‡∏¥‡πà‡∏á ‡∏ú‡∏ç ‡∏¢‡∏¥‡πà‡πâ‡∏á‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á)
-   infections e.g. epstein-barr virus (EBV) or Mycobacterium (‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡πÅ‡∏Ñ‡πà TB)
-   obesity
-   alcohol ‚Üí ‡∏°‡∏µ‡∏ú‡∏•‡∏Å‡∏±‡∏ö inflammation
-   ‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡πÅ‡∏î‡∏á‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏•‡∏∑‡∏≠ (‡∏°‡∏±‡∏ô‡πÄ‡∏™‡∏£‡∏¥‡∏°‡∏≠‡πâ‡∏≠‡∏° ‡πÜ‡πó
-   vit.D def

## Symptoms
-   ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÉ‡∏ô‡∏Ç‡πâ‡∏≠
	-   Hallmark = persistent **symmetric** polyarthritis (synovitis) that affects the hands and feet
	-   Joint inflammation (tnf, il-1, il-6 ‡πÄ‡∏õ‡πá‡∏ô key substance ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö)
	-   Morning Stiffness ‡∏ï‡πà‡∏≠‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á**‡πÄ‡∏Å‡∏¥‡∏ô 1 ‡∏ä‡∏°** (ex. ‡πÄ‡∏õ‡∏¥‡∏î‡∏Ç‡∏ß‡∏î‡∏ô‡πâ‡∏≥‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡∏ó‡∏≥‡∏Å‡∏¥‡∏à‡∏ß‡∏±‡∏ï‡∏£‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ß‡∏±‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ)
	-   ‡πÄ‡∏Å‡∏¥‡∏î‡∏ô‡∏≤‡∏ô‡∏Å‡∏ß‡πà‡∏≤ 6 wks
	-   ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏±‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏õ‡∏•‡∏≤‡∏¢‡∏°‡∏∑‡∏≠ ‡∏õ‡∏•‡∏≤‡∏¢‡πÄ‡∏ó‡πâ‡∏≤
		- ![[Pasted image 20221201143640.png\|Pasted image 20221201143640.png]]
		-   DIP ‡∏Ç‡πâ‡∏≠‡∏ô‡∏¥‡πâ‡∏ß‡∏°‡∏∑‡∏≠**‡∏õ‡∏•‡∏≤‡∏¢** (memo: D = distal)
		-   PIP ‡∏Ç‡πâ‡∏≠‡∏ô‡∏¥‡πâ‡∏ß**‡∏™‡πà‡∏ß‡∏ô‡∏ï‡πâ‡∏ô**
		-   MCP or MTP ‡∏Ç‡πâ‡∏≠‡∏ô‡∏¥‡πâ‡∏ß**‡∏™‡πà‡∏ß‡∏ô‡πÇ‡∏Ñ‡∏ô**
-   ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≠‡∏Å‡∏Ç‡πâ‡∏≠
	-   **lethargy**
	-   weight loss
	-   low fever
	-   ‡∏õ‡∏∏‡πà‡∏° / ‡∏Å‡πâ‡∏≠‡∏ô‡∏£‡∏π‡∏°‡∏≤‡∏ï‡∏≠‡∏¢‡∏î‡πå‡πÉ‡∏ï‡πâ‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á specific) ex. ‡∏õ‡∏•‡∏≤‡∏¢‡∏®‡∏≠‡∏Å
	-   ‡∏ô‡∏≠‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏ô‡∏≤‡∏ô‡∏ñ‡∏∂‡∏á‡∏à‡∏∞‡πÄ‡∏à‡∏≠ ‚Üí interstitial lung disease or plueral disease, vasculitis, keratoconjuctivitis sicca, sceleritis, or sjogren's syndrome, **pericardidtis, cardiac conduction abnormalities**, or myocarditis, felty syndrome or anemia
-   LAB (Synovial Fluid)
	-   ‡∏ñ‡πâ‡∏≤‡πÄ‡∏à‡∏≠‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ ‚Üí ‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠
	-   ‡∏ñ‡πâ‡∏≤‡πÄ‡∏à‡∏≠ crystal ‚Üí gout
	-   ‡∏ñ‡πâ‡∏≤‡∏à‡∏∞ RA ‚Üí ‡πÅ‡∏Ñ‡πà WBC ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ç‡∏∂‡πâ‡∏ô
		-   CRP and ESR ‡πÄ‡∏Ç‡πâ‡∏°‡∏Ç‡πâ‡∏ô‡πÅ‡∏ï‡πà‡∏°‡∏±‡∏ô‡πÑ‡∏°‡πà specific
		-   Rheumatoid Factor (RF, measurement of IgM and IgA subtpyes) ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ specific ‡∏Å‡∏ß‡πà‡∏≤‡πÅ‡∏ï‡πà‡∏™‡∏°‡∏±‡∏¢‡∏ô‡∏µ‡πâ‡πÄ‡∏Ç‡∏≤‡∏à‡∏∞‡πÉ‡∏ä‡πâ.. ACPA (anti-citrullinated peptide antibodies, measurement of IgG subtpyes) ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡∏à‡∏∞ specific ‡∏Å‡∏ß‡πà‡∏≤‡πÅ‡∏ô‡πà‡∏ô‡∏≠‡∏ô ‡πÇ‡∏î‡∏ô‡∏à‡∏∞‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡πÄ‡∏à‡∏≤‡∏∞‡πÄ‡∏≠‡∏≤‡∏ß‡πà‡∏≤ RF or ACPA ‚Üí ‡∏ã‡∏∂‡πà‡∏á‡∏°‡∏±‡∏ô‡∏à‡∏∞‡∏ö‡∏≠‡∏Å prognosis ‡πÑ‡∏î‡πâ **(‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏ô‡∏≤‡∏¢‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î‡πÇ‡∏£‡∏Ñ ‡∏°‡∏±‡∏ô‡∏ö‡∏≠‡∏Å‡πÅ‡∏Ñ‡πà‡πÇ‡∏≠‡∏Å‡∏≤‡∏™‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î ‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏¢‡∏±‡∏á‡πÑ‡∏á ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏à‡∏∞‡∏¢‡∏±‡∏á‡πÑ‡∏á‡∏ô‡∏∞)**
-   X-Ray (gold standard of way to dx)
	-   early stage ‡∏à‡∏∞‡πÅ‡∏Ñ‡πà capsule ‡∏ä‡∏¥‡∏î‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ late stage ‡∏à‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏Å‡∏£‡πà‡∏≠‡∏ô‡∏•‡∏∞
## Diagnosis
-   ‡∏´‡∏°‡∏≠‡∏à‡∏∞‡πÉ‡∏ä‡πâ guideline ‡πÄ‡∏≠‡∏≤
-   FH ‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç
-   LAB (hematology)
-   X-RAY
## Disease Activity
{ #449a0a}

- ‡∏à‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÅ‡∏ö‡πà‡∏á‡πÄ‡∏õ‡πá‡∏ô ‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢ ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á ‡∏†‡∏≤‡∏ß‡∏∞‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å
-   ‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢ ‚Üí ‡πÉ‡∏´‡πâ‡πÇ‡∏£‡∏Ñ‡πÄ‡∏Ç‡πâ‡∏≤‡∏™‡∏π‡πà‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏á‡∏ö
-   ACR/EULAR **‡πÇ‡∏£‡∏Ñ‡∏™‡∏á‡∏ö‡∏´‡∏°‡∏≤‡∏¢‡∏ñ‡∏∂‡∏á‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡∏Ç‡πâ‡∏≠‡∏ö‡∏ß‡∏° ‚â§ 1 ‡∏Ç‡πâ‡∏≠ ‡∏´‡∏£‡∏∑‡∏≠ SDAI < 3.3**
-   DAS28
	- **‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤ 2.6 ‡∏™‡∏á‡∏ö**
	- 2.6-3.2 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏ô‡πâ‡∏≠‡∏¢
	- 3.2-5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏≤‡∏ô‡∏Å‡∏•‡∏≤‡∏á
	- ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 5.1 ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏°‡∏≤‡∏Å
## Treatment Goal
-   ‡∏•‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏õ‡∏ß‡∏î‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö (NSAIDs, analgesics, glucocorticoids) ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á‡πÅ‡∏£‡∏Å‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏¢‡∏≤ DAMRDs ‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå
-   ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠ DMARDs (‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÉ‡∏´‡πâ‡πÄ‡∏£‡πá‡∏ß‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î ‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞ metrotrexate)
-   ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏Ç‡∏≠‡∏á‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢ (improve sense of well-being)
## Treatment
- Rest ‡∏û‡∏±‡∏Å‡πÉ‡∏ä‡πâ‡∏Ç‡πâ‡∏≠
- Occupational Therapy ‡∏Å‡∏≤‡∏£‡∏à‡∏±‡∏î‡∏ó‡πà‡∏≤‡∏ó‡∏≤‡∏á ‡πÅ‡∏ï‡πà‡∏•‡∏∞‡∏Ñ‡∏ô‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏Å‡∏±‡∏ô ‡πÄ‡∏ä‡πà‡∏ô ‡∏ó‡∏≥‡∏ó‡∏µ‡πà‡∏à‡∏±‡∏ö‡∏Å‡∏£‡∏∞‡∏ó‡∏∞‡πÉ‡∏´‡πâ‡∏°‡∏±‡∏ô‡πÉ‡∏ä‡πâ‡∏á‡πà‡∏≤‡∏¢‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏î‡∏¥‡∏°
- Physical therapy
- medication
- surgery
## Pharmacotherapy
-   Symptomatic treatment
	- ‡∏ñ‡πâ‡∏≤‡∏õ‡∏ß‡∏î‡∏Å‡πá NSAIDs ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏¢‡∏´‡∏ß‡∏±‡∏á‡∏§‡∏ó‡∏ò‡∏¥‡πå anti-inflammatory! individualize ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ nsaids ‡∏î‡πâ‡∏ß‡∏¢ ‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡πÅ‡∏ï‡πà‡∏Ñ‡∏ô
- Glucocorticosteroid ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏£‡∏∞‡∏¢‡∏∞‡∏™‡∏±‡πâ‡∏ô‡πÄ‡∏ó‡πà‡∏≤‡∏ô‡∏±‡πâ‡∏ô ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ first line
	- ‡πÉ‡∏ä‡πâ prednisolone
	- ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡∏ï‡∏±‡∏ß‡∏≠‡∏∑‡πà‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏°‡∏±‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡∏´‡∏£‡∏∑‡∏≠ ‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡∏õ‡∏ß‡∏î‡∏´‡∏ô‡∏±‡∏Å‡∏à‡∏ô‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏ä‡∏µ‡∏ß‡∏¥‡∏ï‡∏õ‡∏£‡∏∞‡∏à‡∏≥‡∏ß‡∏±‡∏ô‡∏ó‡∏≥‡∏´‡πà‡∏≤‡πÄ‡∏´‡∏ß‡πÑ‡∏£‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÄ‡∏•‡∏¢
	- ‡πÄ‡∏£‡∏≤‡∏à‡∏∞‡∏Å‡∏•‡∏±‡∏ß‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ï‡∏¥‡∏î steroid ‡∏°‡∏≤‡∏Å
-   csDMARDs (Conventional Synthesic)
	-   Methotrexate (MTX) :
		- **drug of choice**
		- 7.5 - 25 mg /week every 4-8 weeks
		- ‡πÅ‡∏•‡∏∞‡πÄ‡∏™‡∏£‡∏¥‡∏° folic acid 1-5 mg/day ‡πÉ‡∏´‡πâ PO ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡πÄ‡∏õ‡πá‡∏ô dihydrofolate reductaste inhibitor (‡∏ã‡∏∂‡πà‡∏á‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏•‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏î‡πâ‡∏ß‡∏¢ ‡∏£‡∏∞‡∏ß‡∏±‡∏á myelosuppression)
		- ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á fibrosis pneumonitis and copd (‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô exacarbation)
		- ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡πâ‡∏≠‡∏á ‡πÄ‡∏õ‡πá‡∏ô teratogenic
		- ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡πÉ‡∏ô crcl < 30
		- ‡∏ï‡πâ‡∏≠‡∏á monitor liver function test
		- Antidote: Leucovorin
		- **‡∏ñ‡πâ‡∏≤‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ú‡∏•‡πÉ‡∏´‡πâ‡πÑ‡∏õ‡∏î‡∏π LF or SSZ**
	-   Leflunomide (LF)
		- 100mg/day x 3days then 10-20 mg /days daily ‡∏´‡∏£‡∏∑‡∏≠‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ loading dose ‡∏Å‡πá‡πÑ‡∏î‡πâ
		- pyrimidine synthesis inhibitor
		- ‡∏£‡∏∞‡∏ß‡∏±‡∏á**‡∏ó‡πâ‡∏≠‡∏á‡πÄ‡∏™‡∏µ‡∏¢**, nausea/vomitting ‡πÅ‡∏•‡∏∞ hepatic (jaundice)
		- **‡∏ñ‡πâ‡∏≤ ALT > 3xULN ‡πÉ‡∏´‡πâ‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤**
		- **‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡∏ó‡πâ‡∏≠‡∏á‡∏ï‡πâ‡∏≠‡∏á‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 2 ‡∏õ‡∏µ‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ chelostyramine ‡∏à‡∏±‡∏ö‡∏¢‡∏≤‡∏≠‡∏≠‡∏Å‡∏°‡∏≤**
		- combine MTX ‡πÑ‡∏î‡πâ‡∏ñ‡πâ‡∏≤ disease activity ‡∏™‡∏π‡∏á ‡πÇ‡∏î‡∏¢‡πÄ‡∏£‡∏¥‡πà‡∏° MTX ‡∏ó‡∏µ‡πà 10mg/d ‚Üí ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ú‡∏•‡∏≠‡∏µ‡∏Å‡πÑ‡∏õ SSZ ‡πÄ‡∏•‡∏¢ **‡πÑ‡∏°‡πà‡∏Å‡πá combine ‡∏Å‡∏±‡∏ö SSZ?**
	-   Sulfasalazine (SSZ) :
		- Inhibit COX and PGE2; leukotriene and cytokine (unclear)
		- 500 mg - 1 g po OD or 500 mg po bid ‡∏Å‡πá‡πÑ‡∏î‡πâ ‡∏•‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Ç‡∏ô‡∏≤‡∏î‡∏ó‡∏∏‡∏Å 1-2 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå‡∏à‡∏ô‡∏ñ‡∏∂‡∏á 1 g po bid (‡πÄ‡∏û‡∏¥‡πà‡∏° 500mg/day) (max 2-3 g/d) //‡∏¢‡∏≤‡∏°‡∏±‡∏ô‡πÄ‡∏°‡πá‡∏î‡∏•‡∏∞500
		- **‡∏£‡∏∞‡∏ß‡∏±‡∏á urine and skin discoloration ‡πÅ‡∏•‡∏∞‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡πâ‡∏≠‡∏á**
		- ‡∏£‡∏∞‡∏ß‡∏±‡∏á G6PD
	-   Hydroxychloroquine (HCQ) :
		- 400-600 mg OD x 4-12 wks ‡πÅ‡∏•‡∏∞‡∏•‡∏î‡πÄ‡∏´‡∏•‡∏∑‡∏≠ 200-40mg OD
		- ‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà mild case ‡∏à‡∏£‡∏¥‡∏á ‡πÜ (‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ô‡∏≠‡∏Å‡∏Ç‡πâ‡∏≠‡πÄ‡∏¢‡∏≠‡∏∞)
		- ‡πÉ‡∏ä‡πâ‡πÅ‡∏ö‡∏ö triple ‡πÑ‡∏î‡πâ MTX-SSZ-HCQ
		- **‡∏£‡∏∞‡∏ß‡∏±‡∏á irreversible retina damage** ‡πÅ‡∏•‡∏∞‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÉ‡∏´‡πâ‡∏ô‡∏°‡∏ö‡∏∏‡∏ï‡∏£ (‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ‡∏ô‡∏∞)
		- monitor ‡∏ï‡∏≤ , adr = night blindness or preretinopathy
		- 5 ‡∏õ‡∏µ‡πÅ‡∏£‡∏Å‡∏à‡∏∞‡πÄ‡∏à‡∏≠‡∏ô‡πâ‡∏≠‡∏¢ ‡πÅ‡∏ï‡πà‡∏´‡∏•‡∏±‡∏á‡∏à‡∏≤‡∏Å‡∏ô‡∏±‡πâ‡∏ô‡∏Ñ‡∏ß‡∏£‡πÄ‡∏ä‡πá‡∏Ñ‡∏ï‡∏≤‡πÅ‡∏ö‡∏ö annual
-   tsDMARDs (targeted synthetic)
	-   or JAK-inhibitor ‡∏•‡∏á‡∏ó‡πâ‡∏≤‡∏¢‡∏î‡πâ‡∏ß‡∏¢ -nib ‡πÜ‡πÜ ‡∏ô‡∏¥‡∏ö‡πÜ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô Tofacitinib ‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏†‡∏π‡∏°‡∏¥‡∏ï‡πà‡∏≥‡∏ô‡∏π‡πà‡∏ô‡∏ô‡∏µ‡πà ‡πÅ‡∏•‡∏∞‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ‡∏ß‡∏±‡∏Ñ‡∏ã‡∏µ‡∏ô‡πÄ‡∏ä‡∏∑‡πâ‡∏≠‡πÄ‡∏õ‡πá‡∏ô ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏¢‡∏≤‡∏ô‡∏µ‡πâ‡∏°‡∏±‡∏ô‡∏Å‡∏î‡∏†‡∏π‡∏°‡∏¥
-   bDMARDs (biological DMARDs)
	-   ‡∏•‡∏á‡∏ó‡πâ‡∏≤‡∏¢‡∏î‡πâ‡∏ß‡∏¢ -mab -cept ‡πÅ‡∏°‡∏ö‡πÜ‡πÜ‡πÜ ‡πÄ‡∏ã‡πá‡∏ö‡πÜ‡πÜ‡πÜ

> [!Recommendation] 
üí° ‡πÉ‡∏ô guideline ‡∏à‡∏∞‡πÅ‡∏ö‡πà‡∏á‡∏Ñ‡∏≥‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÄ‡∏õ‡πá‡∏ô 3 phase 
1: ‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡∏ó‡∏µ‡πà‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÄ‡∏Ñ‡∏¢‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö DMARD ‚Üí ‡πÉ‡∏ä‡πâ csDMARD ‡πÑ‡∏õ‡∏°‡∏≤‡∏ô‡∏µ‡πà‡πÅ‡∏´‡∏•‡∏∞‡∏à‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÑ‡∏î‡πâ‡∏ú‡∏•555 
2: ‡πÄ‡∏Ñ‡∏¢‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö csDMARD ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ú‡∏• ‚Üí ‡∏Å‡πá‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ bDMARD or JAK-inhibitor 
3: ‡πÄ‡∏Ñ‡∏¢‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö bDMARD or tsDMARD ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ú‡∏•‡∏´‡∏°‡∏î‡πÄ‡∏•‡∏¢ ‡∏Å‡πá‡∏ó‡∏≥‡πÑ‡∏£‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏≠‡πà‡∏∞ ‡πÉ‡∏ä‡πâ‡∏™‡∏±‡∏Å‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πà‡πÅ‡∏´‡∏•‡∏∞ bDMARD or JAK-inhibitor ‡∏™‡∏•‡∏±‡∏ö‡πÑ‡∏õ‡∏°‡∏≤‡πÜ‡πÜ‡πÜ

![[E33175C9-2E09-48E1-9489-6AC847471E5D.jpeg\|800]]

-   ‡πÄ‡∏£‡∏¥‡πà‡∏° DMARDs ‡πÉ‡∏´‡πâ‡πÄ‡∏£‡πá‡∏ß
-   ‡πÉ‡∏ä‡πâ MTX ‡πÄ‡∏õ‡πá‡∏ô drug of choice
-   Steroid ‡πÉ‡∏ä‡πâ short-term ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏£‡∏≠ csDMARDs ‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå ‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏ó‡∏µ‡πà‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ‡πÑ‡∏°‡πà‡πÑ‡∏´‡∏ß‡∏à‡∏£‡∏¥‡∏á ‡πÜ ‡∏ñ‡πâ‡∏≤‡πÑ‡∏´‡∏ß‡∏Å‡πá‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ‡∏û‡∏ß‡∏Å NSAIDs ‡πÑ‡∏£‡∏û‡∏ß‡∏Å‡∏ô‡∏µ‡πâ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤

## Follow-up
-   **efficacy q3mo ‡∏ñ‡πâ‡∏≤ 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏¢‡∏±‡∏á‡πÇ‡∏≠‡πÄ‡∏Ñ ‡∏Å‡πá‡∏ï‡∏±‡∏î‡∏™‡∏¥‡∏ô‡πÉ‡∏à‡∏ï‡πà‡∏≠‡∏ß‡πà‡∏≤‡πÄ‡∏≠‡∏≤‡πÑ‡∏á‡∏î‡∏µ‡∏ñ‡πâ‡∏≤‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏î‡∏µ‡∏Å‡πá‡∏ú‡∏™‡∏°‡πÜ‡πÜ‡∏¢‡∏≤‡πÉ‡∏´‡∏°‡πà ‡πÑ‡∏°‡πà‡∏Å‡πá‡πÄ‡∏Ç‡πâ‡∏≤ phase 2**
-   side eff q4wk or q1mo
-   ‡∏à‡∏£‡∏¥‡∏á ‡πÜ ‡∏Å‡πá‡∏ô‡∏±‡∏î‡πÄ‡∏à‡∏≠‡∏ó‡∏∏‡∏Å‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡∏ô‡∏±‡πà‡∏ô‡πÅ‡∏´‡∏•‡∏∞ ‡∏à‡∏ô‡∏Å‡∏ß‡πà‡∏≤‡∏ô‡∏¥‡πà‡∏á‡∏Ñ‡πà‡∏≠‡∏¢‡∏Ç‡∏¢‡∏±‡∏ö
-   MTX ‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° CXR
-   HCQ or CQ ‡∏ï‡∏£‡∏ß‡∏à‡∏ï‡∏≤
-   Steroid ‡∏£‡∏∞‡∏ß‡∏±‡∏á TB ‡πÅ‡∏ù‡∏á (‡πÄ‡∏î‡∏∞‡∏°‡∏±‡∏ô‡πÄ‡∏ö‡∏¥‡∏Å‡∏ö‡∏≤‡∏ô‡πÉ‡∏à‡∏ñ‡πâ‡∏≤‡∏°‡∏µ‡πÄ‡∏ä‡∏∑‡πâ‡∏≠) ‡∏Å‡πá‡∏ï‡πâ‡∏≠‡∏á CXR ‡∏Å‡∏±‡∏ô‡πÑ‡∏ß‡πâ
-   ‡∏û‡∏ß‡∏Å CXR / ‡∏à‡∏≠‡∏õ‡∏£‡∏∞‡∏™‡∏≤‡∏ó‡∏ï‡∏≤ / FBS / lipid profile ‡πÅ‡∏Ñ‡πà q1yrs ‡∏û‡∏≠‡πÅ‡∏ï‡πà‡∏ó‡∏µ‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠ q1-3mo